| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8dbdfc93841b3d731fbab7ea48b412a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate |
1985-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fed1893d6664234744c4357f5e6fc63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57791163535345e6c178a526d3f55d4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afaf98f67fbdba3baccf4f65f25b6bde |
| publicationDate |
1987-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DE-3545949-A1 |
| titleOfInvention |
NEW DRUG COMBINATIONS AND THEIR USE |
| abstract |
The antiallergic effect of beta 2 mimetics is considerably increased when they are used in combination with a dose which, on its own, is just insufficient for activity (threshold dose) of 11-oxo-11-H-pyrido[2,1-b]quinazoline-2-carboxylic acid or its salts. |
| priorityDate |
1985-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |